Ascendis to Present Early Data on TransCon CNP in Achondroplasia Infants at ESPE 2026 — Ascendis Pharma A/S

Event summary

Ascendis Pharma will present data from its pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years at ESPE 2026.
The presentation will include the first sentinel cohort data from the trial, highlighting early medical intervention in infants with achondroplasia.
Ascendis will also showcase data on hypoparathyroidism and growth hormone indications through posters and e-posters at the conference.
The conference will be held from September 8-10, 2026, in Marseille, France.

The big picture

Ascendis Pharma is positioning itself as a leader in the treatment of rare endocrine diseases, particularly in pediatric populations. The presentation of early data from the reACHin Trial at ESPE 2026 is a strategic move to showcase its innovative TransCon technology platform and its potential to address unmet medical needs in achondroplasia. The company's focus on early intervention in infants with achondroplasia could set a new standard in the treatment of this condition, potentially expanding its market reach and reinforcing its competitive edge in the biopharmaceutical industry.

What we're watching

Clinical Efficacy: How the early data from the reACHin Trial will influence the perception of TransCon CNP's potential in treating achondroplasia in infants.
Regulatory Pathway: Whether the positive data will accelerate the regulatory approval process for TransCon CNP.
Market Positioning: The pace at which Ascendis can establish leadership in the endocrinology rare disease space with its growing portfolio.